 9 Meters Biopharma Inc NASDAQ: NMTR completed a pre-specified interim analysis for the Phase 3 study of larazotide for patients with celiac disease who continue to experience gastrointestinal symptoms while adhering to a gluten-free diet. Based on consultation with the independent. 